Can we prevent stent restenosis after coronary stent implantation

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park, MD, PhD, University.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Could an antianginal metabolic agent have an impact on prognosis in ischemic patients? Beneficial effects of trimetazidine in patients with acute myocardial.
4S: Scandinavian Simvastatin Survival Study
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Presented by Dr. Leif Thuesen
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
European Heart Association Journal 2007 April
Section 5: Intervention and drug therapy
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
Fewer PCIs After Public Reporting Changes in NY
Giuseppe Biondi Zoccai, MD
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
American Heart Association Presented by Dr. Julinda Mehilli
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Nat. Rev. Cardiol. doi: /nrcardio
Maintenance of Long-Term Clinical Benefit with
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
Section C: Clinical trial update: Oral antiplatelet therapy
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Can we prevent stent restenosis after coronary stent implantation Can we prevent stent restenosis after coronary stent implantation? Benefits of trimetazidine on the incidence of stent restenosis after percutaneous coronary intervention. Chen J et al. Int J Cardiol. 2014;173(3):597-600.

Preventive effect of trimetazidine on post-PCI restenosis INTRODUCTION In previous studies, pretreatment with trimetazidine has been shown to prevent myocardial injury during percutaneous coronary intervention.1 Trimetazidine has also been shown to reduce recurrent angina, and to preserve left ventricular function after PCI.2 Despite successful PCI, and despite the introduction of a drug-eluting stent (DES), patients are still highly prone to restenosis.3 The present study investigates whether trimetazidine could also have a beneficial effect on the occurrence and progression of stent restenosis. 1. Bonello L et al. Heart. 2007;93:703-707. 2. Xu X et al. Clin Drug Investig 2014;34:251–258. 3. Chen J et al. Int J Cardiol. (2014) 2014;173(3):597-600.

Preventive effect of trimetazidine on post-PCI restenosis METHODOLOGY 768 patients undergoing PCI for the first time randomized into the trimetazidine group (n=384) and control group (n=384). After DES implantation, all patients were treated with regular medication. In the trimetazidine group, trimetazidine was administrated at 20 mg tid* for at least 30 days. All patients received blinded follow-up angiography 9 to 13 months after discharge. Primary end point: Restenosis Secondary end point: Major adverse cardiac and cerebrovascular events (MACCEs). 768 patients were enrolled and randomized into the trimetazidine group (n=384) and control group (n=384). After DES implantation, all patients were treated with regular medication including double antiplatelet therapy (aspirin at 100 mg/day, indefinitely, and clopidogrel was administered at 75 mg/day for at least 1 year), statins of different doses indefinitely, and other drugs if necessary. In the trimetazidine group, trimetazidine was administrated at 20 mg tid for at least 30 days. All patients received follow-up angiography 9 to 13 months after discharge. Angiographic restenosis was defined as 50% or more luminal narrowing in the target lesion. Major adverse cardiac and cerebrovascular events (MACCEs) were recorded. Chen J et al. Int J Cardiol. 2014;173(3):597-600. *Trimetazidine 20 mg tid is equivalent to trimetazidine 35 mg bid.

Preventive effect of trimetazidine on post-PCI restenosis RESULTS Results on restenosis The trimetazidine group has a lower incidence of stent restenosis compared with the control group (4.2% vs 11.1%; P=0.001). % of events P=0.001 11.1 This result suggests that trimetazidine treatment reduced stent restenosis by 62.2%, compared with control. 4.2 Chen J et al. Int J Cardiol. 2014;173(3):597-600.

Preventive effect of trimetazidine on post-PCI restenosis RESULTS Results on restenosis and the number of MACCEs The incidence of MACCEs is also significantly decreased in the trimetazidine treatment group at the 1-year follow-up visit (6.1% vs 10.8%; P=0.034). This result suggests that trimetazidine treatment reduced the number of MACCEs by 43.5% compared with no treatment. MACCEs include: death from any cause, nonfatal myocardial infarction, revascularization stroke, and cerebral bleeding. Chen J et al. Int J Cardiol. 2014;173(3):597-600.

Preventive effect of trimetazidine on post-PCI restenosis RESULTS Results on predictors for stent restenosis Several predictors for stent restenosis have been identified. Among these predictors, diabetes mellitus, current smoking, stent diameter and length, and age have been shown to stimulate restenosis, while trimetazidine has been shown to prevent restenosis. This study also identified several predictors for stent restenosis after PCI at the 1-year follow-up exam. Trimetazidine treatment has been shown to be a predictor of protection against stent restenosis after PCI. Similar to the results of other studies, we found that age, diabetes mellitus, current smoking, mean stent length, and mean stent diameter were also associated with stent restenosis. Trimetazidine: a predictor of protection Chen J et al. Int J Cardiol. 2014;173(3):597-600.

Preventive effect of trimetazidine on post-PCI restenosis CONCLUSION Even after successful PCI with DES, patients need to be better protected against restenosis. Trimetazidine seems to be protective against stent restenosis in angina patients who undergo PCI. Trimetazidine also may effectively prevent the occurrence of MACCEs. Myocardial injury prevention during PCI and reduction of post-PCI angina symptoms persistence have been observed with trimetazidine All these results suggest that trimetazidine should be combined early in the management of ischemic patients to protect their heart, especially when they undergo PCI. According to the authors, trimetazidine treatment could also improve endothelial dysfunction and preserve heart function after stent implantation. This could explain the results of this study. It is well known that vascular endothelial cells normally provide an efficient barrier against thrombosis, lipid uptake, and inflammation, and the endothelium is critical in the pathology of atherosclerosis and stent restenosis. In recent years, more and more studies have found that, in some patients, stent restenosis is not the result of proliferation and migration of smooth muscle cells, but rather the result of in-stent neoatherosclerosis due to the delay of re-endothelialization at the area of the stent. Therefore, drugs with the ability to protect the endothelium or accelerate endothelial recovery would be helpful to post-PCI patients. Thus, it seems that the effect of trimetazidine on the endothelium could contribute greatly to its role in the inhibition of stent restenosis observed in our study. Chen J et al. Int J Cardiol. 2014;173(3):597-600.